The Supreme Court’s decision to review Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc. places renewed attention on a familiar but unsettled issue in pharmaceutical patent law: how the induced infringement doctrine applies when a generic drug launches with a concededly “skinny” label, but engages in broader marketing and communications outside the FDA-approved label.

Although the case arises under the Hatch-Waxman Act, it squarely implicates the scope and enforceability of method-of-use patents, particularly for later-developed indications that often represent substantial additional investment by brand-name manufacturers.

Background: Skinny Labels and Vascepa

Amarin markets Vascepa®, which has two FDA-approved indications: an earlier, unpatented indication for severe hypertriglyceridemia and a later, patented indication for reducing cardiovascular risk. The latter indication was approved years after Vascepa first entered the market and is protected by method-of-use patents reflecting extensive additional clinical development.

Hikma obtained FDA approval for a generic version of Vascepa using a Section viii carve-out, omitting the patented cardiovascular indication from its label. The parties and the courts agree on one key point: Hikma’s FDA-approved label itself does not expressly instruct use of the patented method.

The dispute instead centers on Hikma’s conduct outside the label. Amarin alleges that Hikma induced infringement through press releases and website statements describing its product as a “generic version” or “generic equivalent” of Vascepa and by referencing Vascepa’s overall sales—sales Amarin contends were driven primarily by the patented cardiovascular indication.

The district court dismissed the complaint, holding that these allegations failed to plead the “active steps” required for inducement. The Federal Circuit reversed, concluding that the totality of the alleged conduct plausibly suggested encouragement of infringing use and therefore warranted discovery. The Supreme Court granted certiorari.

Key Issues Before the Supreme Court

What does “active” inducement mean in practice?

Section 271(b) requires “active” inducement, but courts have long recognized that inducement does not require explicit instructions reciting claim language. Amarin argues that encouragement may be inferred from context—particularly where a generic manufacturer markets its product as interchangeable with a branded drug whose most commercially significant use is patented.

From that perspective, the question is not whether Hikma explicitly promoted the patented indication, but whether its communications plausibly encouraged physicians to use the product in the same way they were already using the branded drug.

How much weight should be given to physician sophistication?

Amarin emphasizes that prescribing physicians are highly knowledgeable and well aware of Vascepa’s cardiovascular indication, which has been widely publicized and clinically significant. The Federal Circuit credited the possibility that such physicians could interpret “generic equivalent” statements—combined with sales data—as signaling suitability for the same therapeutic use.

This framing underscores a broader concern for brand companies: if inducement analysis ignores how real-world prescribing decisions are made, later-developed indications may be effectively stripped of meaningful patent protection.

Should inducement claims survive when the label is non-infringing?

The Federal Circuit took care to note that this case does not rest on the label alone. Instead, it focused on whether non-label communications, taken together, plausibly crossed the line from lawful competition into encouragement of patented use. The Supreme Court’s decision may clarify whether compliance with Section viii is sufficient to foreclose inducement liability, or whether post-launch conduct remains fair game.

Key Takeaways from the Briefing

Method-of-use patents remain central to innovation incentives.

Later-approved indications often require substantial investment well beyond the original drug approval. Amarin and its supporters argue that weakening inducement doctrine in the skinny-label context risks eroding the value of those patents and discouraging follow-on innovation.

Skinny labels are not absolute shields.

While Section viii allows generics to omit patented uses from their labels, the Federal Circuit’s decision reflects a view that Hatch-Waxman was never intended to immunize all other conduct—particularly marketing that arguably trades on the success of patented indications.

The government’s position does not resolve the balance.

Although the United States warns against over-deterring generic entry, it also acknowledges that Congress preserved inducement liability as a backstop when generics actively encourage patented uses. The case turns on where that line should be drawn.

The pleading stage matters.

For brand companies, the Federal Circuit’s approach offers reassurance that inducement claims will not be categorically foreclosed before discovery, particularly where context and intent may be illuminated through evidence of marketing strategy and physician targeting.

Takeaway

Hikma v. Amarin asks the Supreme Court to calibrate the boundary between lawful generic competition and protection of patented methods of use. While Hatch-Waxman facilitates generic entry for unpatented indications, it also preserves inducement liability to safeguard later-developed innovations. The Court’s decision will clarify how those principles coexist—and how much room branded pharmaceutical companies have to enforce method-of-use patents when generics market alongside them.